Compare MAIN & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAIN | MMED |
|---|---|---|
| Founded | 2007 | 1983 |
| Country | United States | United States |
| Employees | N/A | 2800 |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.3B |
| IPO Year | 2014 | 2026 |
| Metric | MAIN | MMED |
|---|---|---|
| Price | $55.28 | $17.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $61.57 | $22.56 |
| AVG Volume (30 Days) | 613.6K | ★ 1.0M |
| Earning Date | 05-07-2026 | 06-03-2026 |
| Dividend Yield | ★ 8.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.27 | $15.99 |
| Revenue Next Year | $5.14 | $10.00 |
| P/E Ratio | $57.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.95 | $10.65 |
| 52 Week High | $67.77 | $17.86 |
| Indicator | MAIN | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 70.03 |
| Support Level | $54.60 | $14.70 |
| Resistance Level | $58.82 | N/A |
| Average True Range (ATR) | 1.18 | 0.91 |
| MACD | 0.09 | 0.13 |
| Stochastic Oscillator | 78.44 | 86.34 |
Main Street Capital Corp is a principal investment firm focused on providing customized long-term debt and equity capital solutions to lower middle market ("LMM") companies and debt capital to private ("Private Loan") companies owned by or in the process of being acquired by a private equity fund. The group invests principally in secured debt investments, equity investments, warrants, and other securities of LMM companies, typically based in the U.S. The company operates as a single segment with a principal investment objective to maximize total return by generating current income from debt investments and current income and capital appreciation from equity and equity-related investments.
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.